Lowering the price of medicine becomes the main theme, making medicine steadfastly without worrying about the market

Medical network January 15 news to solve the problem of "expensive medical treatment" for the common people, has always been one of the main tasks of the new medical reform, and the high drug price is one of the "culprits" of "expensive medical treatment" for the common people In order to solve the problem of false high drug price, the national and local levels have been trying and exploring, and through the implementation of special procurement of anti-cancer drugs, zero tariff volume procurement, price negotiations and other ways to reduce drug prices In 2019, under the general trend of "drug price reduction", it seems that it is a dilemma for pharmaceutical companies whether to protect the market or the price Experts in the industry say that the fundamental way to break through is to make conscience medicine, win with quality, focus on independent research and development and innovation, and make sure that no one has what he has and no one has what he has The game of "drug price" between pharmaceutical enterprises and local governments In December 2018, the centralized purchase network of drugs and medical consumables of Liaoning Province issued the notice on the implementation of the results of tax reduction and price reduction of domestic anti-cancer drugs (hereinafter referred to as the notice), which said that 125 drugs without tax reduction impact, application for no price reduction, relevant certification materials of accounting firm and submission of no materials will be suspended from online purchase in Liaoning Province, From 0:00 on December 25, 2018 According to statistics, there are 60 pharmaceutical enterprises that have lost the qualification of online purchasing, many of which have suspended trading of multiple specifications These drugs that have lost the qualification to be connected to the Internet can be roughly divided into the following situations: Two drugs applied for no price reduction in the name of "not affected by tax reduction", but they did not provide relevant supporting materials and were not recognized by the centralized purchase platform; 57 drugs were disqualified for a certain degree of reduction, but failed to meet the requirements of the centralized purchase platform; 66 product rules did not respond to their price reduction needs at all However, on December 29, 42 domestic anti-cancer drugs from 21 drug manufacturers including Jiangsu Hengrui Pharmaceutical Co., Ltd applied for tax reduction and price reduction and resumed online purchasing On December 30, online purchasing was resumed and new online purchasing qualification was implemented It is understood that since May 1, 2018, China has started to implement "zero tariff" for anti-cancer drugs and other drugs Many local governments therefore require drug companies to reduce their prices The suspension of online purchasing qualification of drug companies in Liaoning Province is one of the measures taken for drug companies not to reduce their prices or prices are not in place Wei Baixing, the founder of drug price reduction network, expressed great disapproval of such measures by local governments "In China's health care reform, are there few jokes from local governments?" he said? Some time ago, Liaoning Province also announced that the bidding price of azithromycin 0.25g * 6 tablets was nearly 50 yuan Are there many high-priced drugs in their backstage database? In the whole process of medical reform for ten years, the local government has been deceiving the upper and the lower, fooling around, remembering that the price of drugs is getting higher and higher, even including the price of common drugs In other words, the local government is not only the culprit of pushing up the drug price, but also the biggest beneficiary and umbrella of the interest chain of medical reform " It is unreasonable for local governments to ask drug companies to reduce drug prices on the basis of tax reduction So, what kind of medicine can reduce the price? Wei boxing analyzes that drugs that can be reduced in price are generally inseparable from two characteristics The first feature is that there are many pharmaceutical manufacturers, the market is saturated, and the competition is strong The top three pharmaceutical companies in imitation no longer need to rely on this product to make money To reduce the price of this kind of drugs not only responds to the call of "reducing the price of drugs" of the state, cooperates with the implementation of local policies, obtains a good reputation, but also consolidates the previous sales channels, and lays a foundation for the sales of other drugs within the enterprise It can be said that there are many drugs in one fell swoop The second characteristic is that there are few enterprises competing for this kind of drugs, but there are various side effects, such as drug resistance, etc the enterprises have already listed the same kind of new drugs, and the market prospect is good, so the price of this kind of drugs will be reduced naturally It is better to say that the price has been eliminated by the enterprise Jiangsu Hengrui Pharmaceutical Co., Ltd., Beijing Shuanglu Pharmaceutical Co., Ltd., Qilu Pharmaceutical Co., Ltd and other well-known enterprises are listed in the list of drugs released by Liaoning Province Wei Baixing also gave his own views on the fact that these pharmaceutical companies would rather abandon the qualification of online purchasing than reduce the price of drugs He said that under the current general trend of "drug reform" as the core of medical reform, the reason why enterprises prefer to abandon the Internet without price reduction is that once the price is reduced, it is almost impossible to increase the drug price later, such as some exclusive Chinese patent medicines, metoo medicines, etc Of course, another reason is that enterprises believe that the government's drug price reform will not last for a long time Compared with these enterprises who are unwilling to reduce the drug price, from the information released by drug procurement in the second half of 2018, it can be seen that some pharmaceutical enterprises (mainly including foreign pharmaceutical enterprises and large domestic pharmaceutical enterprises) have chosen to actively reduce the bidding price For the two different choices of different pharmaceutical companies, Wei Baixing said that without price reduction, they may not be able to enter the medical insurance catalog and the basic drug catalog Even if they enter the catalog, they may be eliminated or replaced by other similar products Therefore, there are reasons why pharmaceutical companies choose to reduce their prices actively In addition, the reason why foreign pharmaceutical companies and large domestic pharmaceutical companies choose to reduce prices also conforms to the two characteristics of drug price reduction mentioned above Drug price reform is also good for drug companies Drug price involves solving the problem of "expensive medical treatment" for the common people, which is one of the main tasks of the new medical reform But for a long time, the problem of "expensive medical treatment" has not been solved It can be seen from the 4 + 7 urban centralized procurement pilot at the end of 2018 that the drug price in China is indeed abnormally high As for the reasons for the abnormally high drug prices, Wei Baixing said that 20% of the large Chinese and foreign pharmaceutical enterprises monopolized 80% of the sales share of the pharmaceutical market Driven by huge interests, pharmaceutical enterprises, hospitals, doctors and the government departments of power rent-seeking jointly promoted the abnormally high drug prices in China, especially the government's recruitment department was the core of the crime On the morning of December 28, 2018, the seventh session of the Standing Committee of the 13th National People's Congress held a joint group meeting to carry out a special inquiry on the consideration of the State Council's report on the distribution and use of financial and health funds Sun Chunlan, vice premier of the State Council, said that the problem of inflated drug prices in China is quite prominent Many drugs are more expensive than those in neighboring countries and regions To solve the problem of expensive medical treatment, first of all, we need to reduce the price of drugs that are falsely high Wei boxing agrees with this "Premier Li Keqiang made it clear at the executive meeting of the State Council on April 6, 2016 that" drug prices "should be used as a" breakthrough "in deepening medical reform," he said Two years later, vice premier sun also proposed to take "drug price reduction" as a breakthrough point, plus the current "4 + 7 volume procurement" It can be said that the central government's decision to adjust the core of the current medical reform to drug price is very wise, finding out the core pain points of China's medical reform over the years, and grasping the "bull's nose" to solve the problem of "expensive medical treatment" In order to solve the problem of high drug prices, both the national and local levels have been trying and exploring In addition to the implementation of measures such as special procurement of anticancer drugs and zero tariff, the state also reduces the price of drugs by means of volume procurement and price negotiation "Reducing drug price" has become a major trend Under such a trend, some industry insiders pointed out that just lowering the drug price is not enough As the saying goes, it's better to ask for others than yourself At the moment when target drugs and biopharmaceuticals are basically monopolized by imported drugs, the role of reducing drug prices through tax reduction and negotiation is very limited After all, people with inferior skills have no right to speak In order to solve the problem of "expensive medical treatment", the fundamental way lies in independent research and development and innovation In terms of technology, it is always in the leading position It is the direction that Chinese pharmaceutical enterprises should strive for to achieve the goal that no one has his or her own advantages and no one has his or her own advantages Wei boxing also said that since the country has come out to carry out volume procurement, it is undoubtedly a great advantage for small and medium-sized pharmaceutical enterprises that used to be on the edge of extrusion Only by keeping good product quality and reasonable profits can enterprises reduce their prices to the bottom On the one hand, the state is trying to reduce the drug price, but on the other hand, the cost of pharmaceutical enterprises remains high, such as consistency evaluation, price rise of raw materials, standardized operation, environmental protection, labor, etc If the price of drugs is pulled down, does it mean that the profits of drug companies are also pulled down? Some people said that from another point of view, in fact, drug price reform is also good for drug companies First, to make the competition more transparent, the powerful pharmaceutical enterprises can obtain a larger market share Now the signal from the unified procurement of the medical insurance bureau is: I hope that the pharmaceutical enterprises can control the quality and cost in a down-to-earth way, so there will be a market and money Second, it can make pharmaceutical companies recover the drug payment faster For example, the successful pharmaceutical companies with volume purchase can receive 50% of the advance payment in advance, which is conducive to invigorating the fund of pharmaceutical companies In addition, the market feedback of the first national procurement with volume is also very positive: 25 out of 31 generic drugs are to win the bid, with an average price reduction rate of about 52%, and the maximum reduction rate of 96%, the effect is solid For the development of pharmaceutical enterprises in 2019, Wei Baixing also gives his own suggestions He said that pharmaceutical companies should make conscience medicine, earn reasonable money, improve the level of research and development, and win with quality After all, the era of negative marketing with cunning and fake works has become a past.